Navigation Links
VIA Pharmaceuticals Announces Positive Phase 2 Results of VIA-2291 in Cardiovascular Patients Using Serial MDCT Imaging of Coronary Plaque
Date:5/1/2009

Data Presented at American Heart Association ATVB Conference Shows Reduction in Non-Calcified Plaque Volume and Fewer New Plaque Lesions in Treated Patients

WASHINGTON and SAN FRANCISCO, May 1 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP) today announced the results of a sub-study of patients in its acute coronary syndrome (ACS) Phase 2 trial who received serial 64 slice multidetector computed tomography (MDCT) scans before and after six months of treatment with its lead drug, VIA-2291, an inhibitor of leukotrienes, proposed mediators of vascular inflammation. Results were presented in a poster session at the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference 2009 in Washington, D.C. by Jean-Claude Tardif MD, of the Montreal Heart Institute, and Dr. Rebecca Taub, VIA's Senior Vice President - Research & Development.

Of 191 patients enrolled in the first 12 weeks of the ACS trial, over 85 elected to continue in the study for an additional 12 weeks, receiving either placebo or VIA-2291 on top of current standard medical care. Each of these patients received an MDCT scan at baseline and at 24 weeks. Evaluable scans from patients treated with placebo showed significantly more evidence of new plaque lesions at follow-up than VIA-2291 treated patients. MDCT scans of patients with low density plaques demonstrated statistically significant, lower plaque volumes in combined VIA treated groups compared to placebo. Together these results suggest that VIA-2291 may reduce the progression of unstable coronary plaques that lead to heart attacks and stroke.

Despite advances in treatment, cardiovascular disease remains a leading cause of death and disability in the United States and the world. Emerging research points to the potential for inflammation
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... ... In an article published July 30th by the New York ... highlighting a security firm that is tasked with providing supplemental protection. Called the French ... with the city to provide private security when it is needed in a city ...
(Date:8/27/2015)... ... August 27, 2015 , ... On May 30th, 2015, at the Adams ... sponsor of the “Music With A Mission” benefit concert. For the past two years, ... in the underfunded school districts of Mendon and neighboring town, Quincy, IL. Organized in ...
(Date:8/27/2015)... ... August 27, 2015 , ... Infocast ... for October 27-29, 2015 in San Jose, CA. The first event dedicated ... on the void that exists where battery development and energy storage innovation are ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... ... 27, 2015 , ... For the first time, Ninja® introduces ... Nutri Ninja® Auto-iQ Pro Complete and Nutri Ninja Auto-iQ Compact System. These two ... customization to a whole new level. This line of Nutri Ninja products is ...
Breaking Medicine News(10 mins):Health News:Article on New Orleans Security Force Highlights the Abilities and Flexibility of Private Security, says Spear Security Inc. 2Health News:Best Drug Rehabilitation Interviews Madd Hoss Jackson at the 2015 "Music With A Mission" Benefit Concert 2Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 2Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 3Health News:SharkNinja's Nutri Ninja® Auto-iQ™ Pro Complete Delivers Power And Versatility In A Compact Design 4
... an as yet unknown reason, cancer radiotherapy can increase ... problem that is growing as more and more people ... now suggests that sustained inflammation induced by post-radiotherapy changes ... the cause. Epidemiological studies have shown that ...
... historian Nicholas Everett and Walid Saleh, a scholar of ... each been selected to receive a highly competitive New ... research. It is the first time the fellowships, ... United States. The New Directions Fellowships are ...
... whites at specialized cancer centers, research shows , MONDAY, ... cancer patients receive similar care at specialized cancer centers, ... a U.S. study has found. , The finding suggests ... previous findings of racial disparities in cancer deaths, the ...
... ... ... ... MONTREAL , March 22 /PRNewswire/ - Haemacure Corporation (TSX:HAE) announces that it has obtained authorization from the Superior Court of the Province of Québec to sell ...
... available to parents and pupils about asbestos exposure in schools. The call comes less than a month after a report by the Asbestos Training and Consultancy ... ... , ... ...
... Bakeries Across USA Join Campaign For Epilepsy Awareness , ... , , ... ... NEW YORK , March 22 This week, bakeries across ...
Cached Medicine News:Health News:Radiotherapy can cause lasting vascular disease 2Health News:University of Toronto scholars receive prestigious New Directions Fellowships 2Health News:Where Cancer Treatment Takes Place May Influence Outcome 2Health News:Court Authorizes Haemacure to Sell its Assets and Grants a Second Extension to Make a Proposal to its Creditors 2Health News:First Personal Injury on Asbestos in Schools 2Health News:Purple Cupcake Production on the Rise Nationwide 2Health News:Purple Cupcake Production on the Rise Nationwide 3
(Date:8/27/2015)... Pa. , Aug. 27, 2015  PinnacleHealth CardioVascular Institute ... and second in the United States ... new type of stent for blockages in the main artery ... within the artery and potentially less risk for stent fracture ... is a prospective, single-arm, multicenter clinical trial of the BioMimics ...
(Date:8/27/2015)... , Aug. 27, 2015  Lightwave Logic, ... the development of Next Generation Photonic Devices ... applications in high speed fiber-optic data communications and ... Lebby has been appointed to the Company,s ... in the field of optoelectronics is widely recognized ...
(Date:8/27/2015)... 27, 2015  CytomX Therapeutics, Inc., a biopharmaceutical ... cancer, today announced that Rachel Humphrey , ... of Directors, has been appointed chief medical officer. ... and AstraZeneca, and also oversaw clinical development of ... at Bristol-Myers Squibb and the development of Nexavar ...
Breaking Medicine Technology:First Pennsylvania Patient Treated in Landmark Vascular Study 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 2Lightwave Logic Announces the Appointment of Optoelectronics Industry Leader, Michael Lebby, Ph.D. to its Board of Directors 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3
... Corporation (Nasdaq: OMER ), a biopharmaceutical company ... inflammation and disorders of the central nervous system, today ... call Monday afternoon, October 25, 2010 at 4:00 p.m. ... Demopulos, M.D., chairman and chief executive officer, will provide ...
... 22 Endo Pharmaceuticals (Nasdaq: ENDP ) today announced ... Healthcare Conference on Tuesday, November 2, 2010, at 2:10 p.m. EDT. ... company,s products and development programs. There will be a ... www.endo.com under the investors section. About ...
Cached Medicine Technology:Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update 2
Indications For Usage: ,Single patient use on anesthetized patients and respiratory care patients who require a breathing circuit. The product is intended to be replaced at least once every 24 hours...
... T helps provide protection to the exposed airway ... extremely lightweight making it ideal for active young ... rate of heat and moisture recovery, it ensures ... HMEs and filters have ISO standard tapered ends ...
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... Our variable volume Finnpipette ... in a high performance pipette. ... colour-coded volume range, ensures quality, ... identification of the volume range ...
Medicine Products: